Prevalence and Distribution of Hepatitis C Virus in Iranian Drug User: Systematic Review and Meta-Analysis Study
Abstract
Context: Hepatitis C, as a major public health problem, has serious complications and drug users are the highest risk group for it.
Objectives: As the importance of this subject, the current study has been done to estimate the pooled prevalence and distribution of hepatitis c virus in Iranian Drug User.
Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar and Web of Science and Iranian scientific information database (SID), Health. barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of HCV Iranian Drug User.
Results: 227 records were identified by the electronic search, of which 62 studies were identified as relevant papers which were meta-analyzed for the pooled HCV prevalence. Overall, prevalence of HCV was 42.01 %( 36.83%-47.20%) in Iranian drug user.
Conclusion: Our meta-analysis study showed that HCV prevalence is high in drug users in Iran. With respect to the high prevalence of Hepatitis C among Drug User, ongoing preventive actions for this group are recommended.
1.Adler, M., et al., Hepatitis C virus: the burden of the disease. Acta gastro-enterologica Belgica, 2002. 65(2): p. 83-86.
2.Javadi, A., et al., Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in Drop in centers. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 2014. 19(Suppl 1): p. S17.
3.Averhoff, F.M., N. Glass, and D. Holtzman, Global burden of hepatitis C: considerations for healthcare providers in the United States. Clinical infectious diseases, 2012. 55(suppl_1): p. S10-S15.
4.Van Handel, M.M., et al., County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. Journal of acquired immune deficiency syndromes (1999), 2016. 73(3): p. 323-331.
5.Zafarghandi, M.B.S., M. Jadidi, and N.Khalili, Iran’s activities on prevention, treatment and harm reduction of drug abuse.International journal of high risk behaviors & addiction, 2015. 4(4).
6.Mahmud, S., V. Akbarzadeh, and L.J. AbuRaddad, The epidemiology of hepatitis C virusin Iran: Systematic review and meta-analyses. Sci Rep, 2018. 8(1): p. 017-18296.
7.Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols PRISMA-P) 2015 statement. Systematic Reviews, 2015. 4(1): p. 1.
8.Downes, M.J., et al., Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ open,2016. 6(12): p. e011458.
9.Salehi-Vaziri, M., et al., Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and MetaAnalysis. Hepatitis Monthly, 2016. 16(4): p.e35577.
10.Alavian, S.M., et al., Hepatitis C infection in the general population of Iran: a systematic review. Hepatitis Monthly, 2009. 9(3).
11.Mirminachi, B., et al., Update on the prevalence of hepatitis C virus infection among Iranian general population: a systematic review and meta-analysis. Hepatitis Monthly, 2017.17(2).
12.Shamshirian, A., et al., Seroprevalence and geographical distribution of hepatitis C virus in Iranian patients with thalassemia: a systematic review and meta-analysis, in Journal of Laboratory Medicine2019. p. 45.
13.Behzadifar, M., H.A. Gorji, and N.L. Bragazzi, The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and metaanalysis. Archives of Virology, 2018. 163(5): p.1131-1140.
14.Alavian, s.m., et al., Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodialysis International, 2010.14(3): p. 253-262.
15.Ghorbani, N.R., et al., Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2017. 22: p.123-123.
16.Mohammadi, M., et al., Prevalence of Hepatitis C in Iranian prisoners (2001-2016): A Systematic Review and Meta-analysis. Zanko Journal of Medical Sciences, 2018. 19(60): p. 1-13. 17.Nematollahi, S., et al., Prevalence of hepatitis C virus infection among high-risk groups in Iran: a systematic review and metaanalysis. Public Health, 2018. 161: p. 90-98.
18.Behzadifar, M., et al., Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis.Harm reduction journal, 2018. 15(1): p. 24.
19.Moradi, G., et al., Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio-behavioural survey
in 2015. Trop Med Int Health, 2018. 23(6): p.641-649.
20.Malekinejad, M., et al., High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001–2012). International Journal of Infectious Diseases, 2015. 40: p. 116-130.
21.RostamiJalilian M., Omid Ghaemi M., and Kassaeian N., Relationship of Hepatitis B and C with Deep Vein Thrombosis in I.V Drug Abusers. Journal of Military Medicine, 2006.8(1): p. 78-81.
22.Ataei, B., et al., Hepatitis C in Intravenous Drug Users: Seroprevalence and Risk Factors. Journal of Isfahan Medical School, 2011. 28.
23.Mobasheri zadeh, S., et al., Hepatitis C Screening in Intravenous Drug Users under Treatment with Methadone: An Action Reserch Study. 2011. 28: p. 1572-76.
24.Meshkati, M., et al. Prevalence of Hepatitis B, C and HIV/AIDS in injecting drug users referred to the Behavioral Diseases Counseling Center in 2004. in The first National Congress of infection in drug addicts in Iran. 2007.
25.Tayeri, K., et al., The prevalence of hepatitis B, hepatitis C and associated risk factors in intravenous drug addicts (IVDA) with HIV in Isfahan. Journal Of Isfahan Medical School I.U.M.S), 2008. 26(90): p. 273-78.
26.Sharif, M., A. Sherif, and M. Sayyah, Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian Journal of Sexually Transmitted Diseases, 2009. 30(1): p. 28.
27.Zamani, S., et al., Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited
through peer-driven sampling in Iran. International Journal of Drug Policy, 2010. 21(6): p. 493-500.
28.Meidani, M., et al., Seroprevalence of HTLV1,2 Virus Among Injection Drug Addicts in Isfahan, 2007-2008. The Journal of Shahid Sadoughi University of Medical Sciences, 2009. 17(4): p. 286-290.
29.Ataei, B., et al., Hepatitis C Screening in Intravenuos Drug Users in Golpayegan, Isfahan through Community : Pilot
Study. Journal of Isfahan Medical School,2011. 28.
30.Khorvash, F., M. Fasihi Dastjerdi, and A.Emami Naeini, Paraclinical disorders and prevalence of viral infections in injection drug users. The Journal of Qazvin University of Medical Sciences, 2009. 13(2): p. 23-29.
31.Meshkati, M., et al., Hepatitis C Screening in Isfahan Drop in Centers: An Experience Description. Journal of Isfahan Medical School, 2011. 28(Special Issue on Hepatitis C).
32.Kaffashian, A., et al., The Experience of Hepatitis C Screening among Prison Inmates with Drug Injection History. Journal of Isfahan Medical School, 2011. 28.
33.Kassaian, N., et al., Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran.Int J Prev Med, 2012. 3(Suppl1): p. S156.
34.Nobari, R.F., et al., Identification of patients with hepatitis C virus infection in persons with background of intravenous drug use: the first community announcement-based study from Iran. Int J Prev Med, 2012. 3(Suppl1): p. S170.
35.Norouzi, A., et al. Bioscience-Behavioral Surveillance in Consumers Injection of materials and their sexual partners in cities Karaj, Isfahan and Gorgan. 2011 [cited 23.07.2019 https://www.unodc.org/documents/islamicrepu
blicofiran/Couple_BSS_Final_Report.pdf].
36.Nokhodian, Z., et al., Hepatitis C among intravenous drug users in Isfahan, Iran: a study of seroprevalence and risk factors. International journal of preventive medicine, 2012. 3(Suppl1): p. S131.
37.Salem, F., et al., Prevalence and risk factors of hepatitis B virus genotype D amongst inmates in Alborz Province, Iran: a crosssectional survey. Jundishapur Journal of Microbiology, 2013. 6(6).
38.Taghizadeh Asl, R., et al., Outcomeassessment of a triangular clinic as a harm reduction intervention in Rajaee-Shahr Prison,Iran. Harm reduction journal, 2013. 10(1): p.41.
39.Amini, S., et al., Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health, 2005: p. 41-46.
40.Mir-Nasseri, S., et al., HCV in intravenous drug users. Govaresh, 2005. 10(2): p. 80-86.
41.Zamani, S., et al., Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy, 2007. 18(5): p. 359-63.
42.Aminzadehv, Z. and K. Aghazadeh Sarhangi, Seroepidemiology of HIV, syphilis, Hepatitis B and C in intravenous drug users at Loghman Hakim hospital. Iranian Journal of Medical Microbiology, 2007. 1(3): p. 53-56.
43.Soudbakhsh., et al., Transfusion transmitted virus prevalence rate in IDU patients: a cross sectional study. Tehran University Medical Journal, 2008. 66(4): p. 282-287. 44.Malekinejad, M., Assessment of the use of
respondent-driven sampling for studying populations most at risk of HIV infection2008: University of California, Berkeley.
45.Mir-Nasseri, M.M., et al., Hepatitis C seroprevalence among intravenous drug users in Tehran. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2008. 13(6): p. 295-302.46.Kheirandish, P., et al., Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health, 2009. 86(6): p. 902-8.
47.Hosseini, M., et al., Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. 2010.
48.Talaie, H., et al., The prevalence of hepatitis B, hepatitis C and HIV infections in non-IV drug opioid poisoned patients in Tehran-Iran.Pakistan journal of biological sciences: PJBS,2007. 10(2): p. 220-224.
49.Mir-Nasseri, M.M., et al., Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon, 2011. 11(1): p. 19-22.
50.Alam Mehrjerdi, Z., et al., Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: the first report from Iran. International journal of STD & AIDS, 2014. 25(6): p. 420-427.
51.Mirahmadizadeh, A.R., et al., Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. 2009.
52.Majidi, Prevalence of HIV, hepatitis B and C among drug abusers admitted to ICU of Baharloo hospital in 2010, in Forensic Medicine2012, Tehran University of Medical Sciences: Tehran. 53.Rahimi-Movaghar, A., et al., HIV, hepatitis
C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. International Journal of Infectious Diseases,2010. 14(1): p. e28-e33.
54.Eskandarieh, S., et al., Descriptive Aspects of Injection Drug Users in Iran's National Harm Reduction Program by Methadone Maintenance Treatment. Iran J Public Health, 2013. 42(6): p. 588-93.
55.Zali, M.R., et al., Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Irn Med, 2001. 4(3): p. 115-119.
56.Naderi, N., Epidemiology of hepatitis C in hospitalized addicts in Loghman Hakim Hospital, 2000-2001. . : ; 2003. Tehran, 2003, Shahid Beheshti University of Medical Sciences.
57.Imani, R., A. Karimi, and N. Kasaeian, Assessing relationship between behavioral factors and the prevalence of serum hepatitis B,hepatitis C and HIV among injecting drug users referred to centers of abstinences of substances in Shahrekord, Iran. Journal of Shahrekord University of Medical Sciences (JSKUMS),2004. 8(1): p. 58-62.
58.Karimi, A., P. 483 Seroprevalence of HBV,HCV and HIV among intravenous drug users in Iran. Journal of Clinical Virology, 2006(36): p.S210-S211.
59.Rahbar, A.R., S. Rooholamini, and K. Khoshnood, Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug Policy, 2004. 15(2): p. 151-155.
60.Tavanaee, S.A. and N.M. Khaleghi, Epidemiologic Evaluation And Some Species In Injection Drug Users That Admitted In Infectious Department Of Imam Reza Hospital 2007-2009). Journal Of Medical Council Of I.R.I., 2012. 30(2): p. 155-161.
61.Alavi, S.M. and A. Etemadi, HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan Journal of Medical Sciences, 2007. 23(4): p. 510.
62.Alavi, S.M. and L. Alavi, Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001–2006). Journal of infection and public health, 2009. 2(1): p. 47-51.
63.Khani, M. and M.M. Vakili, Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. 2003.
64.Faranoush, M., et al., Prevalence of hepatitis C resulted from blood transfusion in major thalassemia patients in , Damghan and Garmsar (2002). Hormozgan Medical Journal, 2006. 10(1): p. 77-82.
65.Honarvar, B., et al., Blood-borne hepatitis in opiate users in iran: a poor outlook and urgent need to change screening policy. PLoS One, 2013. 8(12): p. e82230.
66.Salehi, A., et al., Prevalence of HIV, HCV, and high-risk behaviors for substance users in drop in centers in southern Iran. Journal of addiction medicine, 2015. 9(3): p. 181-187.
67.Azizi, A., F. Amirian, and M. Amirian, Prevalence and Associated Factors of Hepatitis C in Self-introduced Substance Abusers. Hayat, 2011. 17(1).
68.Rezaei, F., et al., Social determinants and hepatitis C among people who inject drugs in Kermanshah, Iran: Socioeconomic status, homelessness, and sufficient syringe coverage. Journal of Substance Use, 2017. 22(5): p. 474-478.
69.Sharhani, A., et al., Hepatitis C virus seroprevalence and associated risk factors among male drug injectors in Kermanshah, Iran. Hepat Mon, 2017. 17(10).70.Sarkari, B., et al., High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med, 2012. 15(5): p. 271-4.
71.kalteh, E.A., et al., The Prevalence of Hepatitis C Virus Infection and Its Related Factors in Injectable Addicts in Gorgan Based on logistic regression model, in 2016.
72.Behnaz, K., et al., Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Gorgan prisoners. Journal of Medical Sciences, 2007.7(2): p. 252-254.
73.Rafiei, A.R., et al., Risk factors for hepatitis C virus among high-risk populations intravenous drug addicts and patients with Thalassemia, Hemophilia, Hemodialysis) in Mazandaran. Journal of Mazandaran University of Medical Sciences, 2011. 21(81): p. 32-42.
74.Ghasemian, R., N. Najafi, and K. Amirkhanloo, The study of infections due to injection drug abuse in the injecting drug users hospitalized at Imam Khomeini Hospital in Sari and Razi Hospital in Ghaemshahr in 2007-2009. Journal of Mazandaran University of Medical Sciences, 2011. 21(83): p. 9-15.
75.Sofian, M., et al., Viral hepatitis and HIV infection among injection drug users in a central Iranian City. Journal of addiction medicine, 2012. 6(4): p. 292-296.
76.Ramezani, A., et al., HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care, 2014. 26(9): p. 1122-6.
77.Davoodian, P., et al., Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Brazilian Journal of Infectious Diseases, 2009.
13(5): p. 356-358.
78.Saleh, M., et al., The prevalence of HIV positive hepatitis B and C in the bodies of injectable addicts in Hamedan. sjfm.hbi.ir, 2010. 60(16): p. 253-258.
79.Alizadeh, A.H.M., et al., Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in HamedanIran. World journal of Gastroenterology: WJG, 2005. 11(26): p. 4085.
80.Keramat, F., P. Eini, and M.M. Majzoobi, Seroprevalence of HIV, HBV and HCV in Persons Referred to Hamadan Behavioral Counseling Center, West of Iran. Iran Red Crescent Med J, 2011. 13(1): p. 42-6.
81.Khodadadizadeh, A., et al., The prevalence of HIV, HBV and HCV in narcotic addicted persons referred to the out patient clinic of rafsanjan university of medical sciences in 2003. Journal of Rafsanjan University of Medical Sciences, 2006. 5(1): p. 23-30.
82.Norouzian, H., et al., Prevalence of HCV infections and co-infection with HBV and HIV and associated risk factors among addicts in Drug Treatment Centers, Lorestan Province, Iran. International journal of high risk behaviors & addiction, 2016. 5(1).
2.Javadi, A., et al., Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in Drop in centers. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 2014. 19(Suppl 1): p. S17.
3.Averhoff, F.M., N. Glass, and D. Holtzman, Global burden of hepatitis C: considerations for healthcare providers in the United States. Clinical infectious diseases, 2012. 55(suppl_1): p. S10-S15.
4.Van Handel, M.M., et al., County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. Journal of acquired immune deficiency syndromes (1999), 2016. 73(3): p. 323-331.
5.Zafarghandi, M.B.S., M. Jadidi, and N.Khalili, Iran’s activities on prevention, treatment and harm reduction of drug abuse.International journal of high risk behaviors & addiction, 2015. 4(4).
6.Mahmud, S., V. Akbarzadeh, and L.J. AbuRaddad, The epidemiology of hepatitis C virusin Iran: Systematic review and meta-analyses. Sci Rep, 2018. 8(1): p. 017-18296.
7.Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols PRISMA-P) 2015 statement. Systematic Reviews, 2015. 4(1): p. 1.
8.Downes, M.J., et al., Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ open,2016. 6(12): p. e011458.
9.Salehi-Vaziri, M., et al., Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and MetaAnalysis. Hepatitis Monthly, 2016. 16(4): p.e35577.
10.Alavian, S.M., et al., Hepatitis C infection in the general population of Iran: a systematic review. Hepatitis Monthly, 2009. 9(3).
11.Mirminachi, B., et al., Update on the prevalence of hepatitis C virus infection among Iranian general population: a systematic review and meta-analysis. Hepatitis Monthly, 2017.17(2).
12.Shamshirian, A., et al., Seroprevalence and geographical distribution of hepatitis C virus in Iranian patients with thalassemia: a systematic review and meta-analysis, in Journal of Laboratory Medicine2019. p. 45.
13.Behzadifar, M., H.A. Gorji, and N.L. Bragazzi, The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and metaanalysis. Archives of Virology, 2018. 163(5): p.1131-1140.
14.Alavian, s.m., et al., Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodialysis International, 2010.14(3): p. 253-262.
15.Ghorbani, N.R., et al., Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2017. 22: p.123-123.
16.Mohammadi, M., et al., Prevalence of Hepatitis C in Iranian prisoners (2001-2016): A Systematic Review and Meta-analysis. Zanko Journal of Medical Sciences, 2018. 19(60): p. 1-13. 17.Nematollahi, S., et al., Prevalence of hepatitis C virus infection among high-risk groups in Iran: a systematic review and metaanalysis. Public Health, 2018. 161: p. 90-98.
18.Behzadifar, M., et al., Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis.Harm reduction journal, 2018. 15(1): p. 24.
19.Moradi, G., et al., Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio-behavioural survey
in 2015. Trop Med Int Health, 2018. 23(6): p.641-649.
20.Malekinejad, M., et al., High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001–2012). International Journal of Infectious Diseases, 2015. 40: p. 116-130.
21.RostamiJalilian M., Omid Ghaemi M., and Kassaeian N., Relationship of Hepatitis B and C with Deep Vein Thrombosis in I.V Drug Abusers. Journal of Military Medicine, 2006.8(1): p. 78-81.
22.Ataei, B., et al., Hepatitis C in Intravenous Drug Users: Seroprevalence and Risk Factors. Journal of Isfahan Medical School, 2011. 28.
23.Mobasheri zadeh, S., et al., Hepatitis C Screening in Intravenous Drug Users under Treatment with Methadone: An Action Reserch Study. 2011. 28: p. 1572-76.
24.Meshkati, M., et al. Prevalence of Hepatitis B, C and HIV/AIDS in injecting drug users referred to the Behavioral Diseases Counseling Center in 2004. in The first National Congress of infection in drug addicts in Iran. 2007.
25.Tayeri, K., et al., The prevalence of hepatitis B, hepatitis C and associated risk factors in intravenous drug addicts (IVDA) with HIV in Isfahan. Journal Of Isfahan Medical School I.U.M.S), 2008. 26(90): p. 273-78.
26.Sharif, M., A. Sherif, and M. Sayyah, Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian Journal of Sexually Transmitted Diseases, 2009. 30(1): p. 28.
27.Zamani, S., et al., Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited
through peer-driven sampling in Iran. International Journal of Drug Policy, 2010. 21(6): p. 493-500.
28.Meidani, M., et al., Seroprevalence of HTLV1,2 Virus Among Injection Drug Addicts in Isfahan, 2007-2008. The Journal of Shahid Sadoughi University of Medical Sciences, 2009. 17(4): p. 286-290.
29.Ataei, B., et al., Hepatitis C Screening in Intravenuos Drug Users in Golpayegan, Isfahan through Community : Pilot
Study. Journal of Isfahan Medical School,2011. 28.
30.Khorvash, F., M. Fasihi Dastjerdi, and A.Emami Naeini, Paraclinical disorders and prevalence of viral infections in injection drug users. The Journal of Qazvin University of Medical Sciences, 2009. 13(2): p. 23-29.
31.Meshkati, M., et al., Hepatitis C Screening in Isfahan Drop in Centers: An Experience Description. Journal of Isfahan Medical School, 2011. 28(Special Issue on Hepatitis C).
32.Kaffashian, A., et al., The Experience of Hepatitis C Screening among Prison Inmates with Drug Injection History. Journal of Isfahan Medical School, 2011. 28.
33.Kassaian, N., et al., Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran.Int J Prev Med, 2012. 3(Suppl1): p. S156.
34.Nobari, R.F., et al., Identification of patients with hepatitis C virus infection in persons with background of intravenous drug use: the first community announcement-based study from Iran. Int J Prev Med, 2012. 3(Suppl1): p. S170.
35.Norouzi, A., et al. Bioscience-Behavioral Surveillance in Consumers Injection of materials and their sexual partners in cities Karaj, Isfahan and Gorgan. 2011 [cited 23.07.2019 https://www.unodc.org/documents/islamicrepu
blicofiran/Couple_BSS_Final_Report.pdf].
36.Nokhodian, Z., et al., Hepatitis C among intravenous drug users in Isfahan, Iran: a study of seroprevalence and risk factors. International journal of preventive medicine, 2012. 3(Suppl1): p. S131.
37.Salem, F., et al., Prevalence and risk factors of hepatitis B virus genotype D amongst inmates in Alborz Province, Iran: a crosssectional survey. Jundishapur Journal of Microbiology, 2013. 6(6).
38.Taghizadeh Asl, R., et al., Outcomeassessment of a triangular clinic as a harm reduction intervention in Rajaee-Shahr Prison,Iran. Harm reduction journal, 2013. 10(1): p.41.
39.Amini, S., et al., Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health, 2005: p. 41-46.
40.Mir-Nasseri, S., et al., HCV in intravenous drug users. Govaresh, 2005. 10(2): p. 80-86.
41.Zamani, S., et al., Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy, 2007. 18(5): p. 359-63.
42.Aminzadehv, Z. and K. Aghazadeh Sarhangi, Seroepidemiology of HIV, syphilis, Hepatitis B and C in intravenous drug users at Loghman Hakim hospital. Iranian Journal of Medical Microbiology, 2007. 1(3): p. 53-56.
43.Soudbakhsh., et al., Transfusion transmitted virus prevalence rate in IDU patients: a cross sectional study. Tehran University Medical Journal, 2008. 66(4): p. 282-287. 44.Malekinejad, M., Assessment of the use of
respondent-driven sampling for studying populations most at risk of HIV infection2008: University of California, Berkeley.
45.Mir-Nasseri, M.M., et al., Hepatitis C seroprevalence among intravenous drug users in Tehran. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2008. 13(6): p. 295-302.46.Kheirandish, P., et al., Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health, 2009. 86(6): p. 902-8.
47.Hosseini, M., et al., Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. 2010.
48.Talaie, H., et al., The prevalence of hepatitis B, hepatitis C and HIV infections in non-IV drug opioid poisoned patients in Tehran-Iran.Pakistan journal of biological sciences: PJBS,2007. 10(2): p. 220-224.
49.Mir-Nasseri, M.M., et al., Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon, 2011. 11(1): p. 19-22.
50.Alam Mehrjerdi, Z., et al., Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: the first report from Iran. International journal of STD & AIDS, 2014. 25(6): p. 420-427.
51.Mirahmadizadeh, A.R., et al., Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. 2009.
52.Majidi, Prevalence of HIV, hepatitis B and C among drug abusers admitted to ICU of Baharloo hospital in 2010, in Forensic Medicine2012, Tehran University of Medical Sciences: Tehran. 53.Rahimi-Movaghar, A., et al., HIV, hepatitis
C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. International Journal of Infectious Diseases,2010. 14(1): p. e28-e33.
54.Eskandarieh, S., et al., Descriptive Aspects of Injection Drug Users in Iran's National Harm Reduction Program by Methadone Maintenance Treatment. Iran J Public Health, 2013. 42(6): p. 588-93.
55.Zali, M.R., et al., Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Irn Med, 2001. 4(3): p. 115-119.
56.Naderi, N., Epidemiology of hepatitis C in hospitalized addicts in Loghman Hakim Hospital, 2000-2001. . : ; 2003. Tehran, 2003, Shahid Beheshti University of Medical Sciences.
57.Imani, R., A. Karimi, and N. Kasaeian, Assessing relationship between behavioral factors and the prevalence of serum hepatitis B,hepatitis C and HIV among injecting drug users referred to centers of abstinences of substances in Shahrekord, Iran. Journal of Shahrekord University of Medical Sciences (JSKUMS),2004. 8(1): p. 58-62.
58.Karimi, A., P. 483 Seroprevalence of HBV,HCV and HIV among intravenous drug users in Iran. Journal of Clinical Virology, 2006(36): p.S210-S211.
59.Rahbar, A.R., S. Rooholamini, and K. Khoshnood, Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug Policy, 2004. 15(2): p. 151-155.
60.Tavanaee, S.A. and N.M. Khaleghi, Epidemiologic Evaluation And Some Species In Injection Drug Users That Admitted In Infectious Department Of Imam Reza Hospital 2007-2009). Journal Of Medical Council Of I.R.I., 2012. 30(2): p. 155-161.
61.Alavi, S.M. and A. Etemadi, HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan Journal of Medical Sciences, 2007. 23(4): p. 510.
62.Alavi, S.M. and L. Alavi, Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001–2006). Journal of infection and public health, 2009. 2(1): p. 47-51.
63.Khani, M. and M.M. Vakili, Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. 2003.
64.Faranoush, M., et al., Prevalence of hepatitis C resulted from blood transfusion in major thalassemia patients in , Damghan and Garmsar (2002). Hormozgan Medical Journal, 2006. 10(1): p. 77-82.
65.Honarvar, B., et al., Blood-borne hepatitis in opiate users in iran: a poor outlook and urgent need to change screening policy. PLoS One, 2013. 8(12): p. e82230.
66.Salehi, A., et al., Prevalence of HIV, HCV, and high-risk behaviors for substance users in drop in centers in southern Iran. Journal of addiction medicine, 2015. 9(3): p. 181-187.
67.Azizi, A., F. Amirian, and M. Amirian, Prevalence and Associated Factors of Hepatitis C in Self-introduced Substance Abusers. Hayat, 2011. 17(1).
68.Rezaei, F., et al., Social determinants and hepatitis C among people who inject drugs in Kermanshah, Iran: Socioeconomic status, homelessness, and sufficient syringe coverage. Journal of Substance Use, 2017. 22(5): p. 474-478.
69.Sharhani, A., et al., Hepatitis C virus seroprevalence and associated risk factors among male drug injectors in Kermanshah, Iran. Hepat Mon, 2017. 17(10).70.Sarkari, B., et al., High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med, 2012. 15(5): p. 271-4.
71.kalteh, E.A., et al., The Prevalence of Hepatitis C Virus Infection and Its Related Factors in Injectable Addicts in Gorgan Based on logistic regression model, in 2016.
72.Behnaz, K., et al., Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Gorgan prisoners. Journal of Medical Sciences, 2007.7(2): p. 252-254.
73.Rafiei, A.R., et al., Risk factors for hepatitis C virus among high-risk populations intravenous drug addicts and patients with Thalassemia, Hemophilia, Hemodialysis) in Mazandaran. Journal of Mazandaran University of Medical Sciences, 2011. 21(81): p. 32-42.
74.Ghasemian, R., N. Najafi, and K. Amirkhanloo, The study of infections due to injection drug abuse in the injecting drug users hospitalized at Imam Khomeini Hospital in Sari and Razi Hospital in Ghaemshahr in 2007-2009. Journal of Mazandaran University of Medical Sciences, 2011. 21(83): p. 9-15.
75.Sofian, M., et al., Viral hepatitis and HIV infection among injection drug users in a central Iranian City. Journal of addiction medicine, 2012. 6(4): p. 292-296.
76.Ramezani, A., et al., HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care, 2014. 26(9): p. 1122-6.
77.Davoodian, P., et al., Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Brazilian Journal of Infectious Diseases, 2009.
13(5): p. 356-358.
78.Saleh, M., et al., The prevalence of HIV positive hepatitis B and C in the bodies of injectable addicts in Hamedan. sjfm.hbi.ir, 2010. 60(16): p. 253-258.
79.Alizadeh, A.H.M., et al., Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in HamedanIran. World journal of Gastroenterology: WJG, 2005. 11(26): p. 4085.
80.Keramat, F., P. Eini, and M.M. Majzoobi, Seroprevalence of HIV, HBV and HCV in Persons Referred to Hamadan Behavioral Counseling Center, West of Iran. Iran Red Crescent Med J, 2011. 13(1): p. 42-6.
81.Khodadadizadeh, A., et al., The prevalence of HIV, HBV and HCV in narcotic addicted persons referred to the out patient clinic of rafsanjan university of medical sciences in 2003. Journal of Rafsanjan University of Medical Sciences, 2006. 5(1): p. 23-30.
82.Norouzian, H., et al., Prevalence of HCV infections and co-infection with HBV and HIV and associated risk factors among addicts in Drug Treatment Centers, Lorestan Province, Iran. International journal of high risk behaviors & addiction, 2016. 5(1).
| Files | ||
| Issue | Vol 6 No 1 (2020) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/jbe.v6i1.4752 | |
| Keywords | ||
| Hepatitis C; Iran; Prevalence; Epidemiology; Drug user; Systematic Review | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Najimi-Varzaneh A, Gholami-Fesharaki M. Prevalence and Distribution of Hepatitis C Virus in Iranian Drug User: Systematic Review and Meta-Analysis Study. JBE. 2020;6(1):72-80.
